The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Vasospastic Angina
Interventions
DRUG

Vericiguat

The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT06415227 - The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris | Biotech Hunter | Biotech Hunter